We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic
News

Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic

Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic
News

Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG today announced that it will receive funding of up to EUR 1.5 million from the German Federal Ministry of Education and Research (BMBF) to advance its H3 receptor antagonist programme into the clinic.

Using its CNS expertise coupled with its discovery platform Evotec has successfully identified and optimized H3 receptor antagonists through to preclinical development. This grant will now provide external funding for Evotec to advance the programme through Phase I clinical studies.

The histamine H3 receptor is a drug target of high interest because of evidence that blocking this receptor in the brain can improve cognition, alertness and attention. H3 receptor antagonists therefore have the potential to become an important new class of therapy in a number of CNS indications, including excessive fatigue associated with conditions such as multiple sclerosis.

Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: “We are happy that the Neu² consortium has chosen to support our H3 receptor antagonist programme for further development within the BioPharma initiative. By driving these novel drug candidates from identification through to the first clinical steps, we can optimally capture the commercial value of this programme.”
Advertisement